: rearrangements are present in 2-7% of non-small cell lung cancer (NSCLC) cases, where the fusion is the most frequent. Rearrangement of with other fusion partners occurs only in ≈5% of NSCLC ALK-positive. These patients have benefit from inhibitors and currently, there are three generations of drugs as standard of care. The first generation ALK inhibitor crizotinib is approved in the front line setting for the treatment of advanced NSCLC; unfortunately, these tumors may eventually develop resistance to this molecule. The Second-generation A inhibitors, ceritinib, alectinib and brigatinib, are approved for patients recently diagnosed or in relapse. The third-generation inhibitor lorlatininb is approved for patients who have developed resistance to any ALK inhibitor.: In this review, an unstructured search in Pubmed and SCOPUS was conducted. We summarized the mechanisms of resistance to inhibitors and its consequences in the treatment-decision making in advanced or metastatic NSCLC after failure to a first-line inhibitor.: Currently, there are a growing number of options of therapeutic agents against ALK+ NSCLC (approved and in development); however, adequate selection and sequencing of agents is crucial to deal with the tumor evolution.
May 14, 2013
Plasma Volume Status and its Association with In-Hospital and Post-Discharge Outcomes in Decompensated Heart Failure.
October 12, 2020
Fatal pulmonary infection by trimethoprim-sulfamethoxazole resistant Nocardia otitidiscaviarum: report of two cases and review.
March 9, 2020
- ASCO – Lung CancerASCO.20 Virtual Scientific Program, held May 29 - 31, brought professionals from all over the world together to hear the brightest minds in oncology present state-of-the-art treatment modalities and new therapies.
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.